Work

A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.36_suppl.360922

Authors: Wendy Y. Chen, Karla V. Ballman, Eric P. Winer, Thomas H. Openshaw, Olwen Mary Hahn, Frederick M. Briccetti, William Johnson Irvin, Paula R Pohlmann, Lisa A. Carey, Ann H. Partridge, Anna Weiss, Linda Mackie McCall, Carol Matyka, Margaret Carvan, Michelle D. Holmes

Institutions: Dana-Farber Cancer Institute, Weill Cornell Medicine, Harvard University, Dana-Farber/Harvard Cancer Center, University of Chicago Medical Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Alliance for Clinical Trials in Oncology, Brigham and Women's Hospital

Language: English

Topic: Inflammatory mediators and NSAID effects

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: U.S. Department of Defense, National Institutes of Health

OpenAlex ID: W4220947142

Cites:

Cited by: 15

Related to: 10